A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease (NCT06572384)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belimumab Administered Subcutaneously in Adults With Interstitial Lung Disease (ILD) Associated With Connective Tissue Disease (CTD)
🩺 Plain-English Summary (8th-Grade Level)
Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (131 Sites)
Showing the first 25 of 131 sites.
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — San Francisco, California
- GSK Investigational Site — Upland, California
- GSK Investigational Site — Gainesville, Florida
- GSK Investigational Site — Naples, Florida
- GSK Investigational Site — St Louis, Missouri
- GSK Investigational Site — New York, New York
- GSK Investigational Site — New York, New York
- GSK Investigational Site — Potsdam, New York
- GSK Investigational Site — Durham, North Carolina
- GSK Investigational Site — Philadelphia, Pennsylvania
- GSK Investigational Site — Houston, Texas
- GSK Investigational Site — Temple, Texas
- GSK Investigational Site — Salt Lake City, Utah
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Ciudad Autonoma Buenos Aires,
- GSK Investigational Site — Córdoba,
- GSK Investigational Site — Mendoza,
- GSK Investigational Site — Rosario,
- GSK Investigational Site — San Miguel de Tucumán,
- GSK Investigational Site — Santa Fe,
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Diseases, Interstitial
- Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease — Venice, Florida
- Dorothy P. and Richard P. Simmons Center for ILD Research Registry — Pittsburgh, Pennsylvania
- Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS) — Mexico City,
Explore by condition: All Lung Diseases, Interstitial clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.